An objective of the present invention is to provide a minimally invasive examination method beneficial for the early diagnosis of MND, and a new screening method for therapeutic agents for MND.　This method for examining the risk of developing motor neuron disease comprises a step for measuring the amount of U3 snoRNA or the nuclear localization range of U3 snoRNA-binding proteins with respect to motor neurons differentiated from pluripotent stem cells established from somatic cells of a subject.
MOTOR NEURON DISEASE EXAMINATION METHOD AND THERAPEUTIC AGENT SCREENING METHOD